Back to Journals » Breast Cancer: Targets and Therapy » Volume 11

Immunotherapy for the Treatment of Breast Cancer: Emerging New Data

Authors Mina LA, Lim S, Bahadur SW, Firoz AT

Received 26 September 2019

Accepted for publication 12 December 2019

Published 3 January 2020 Volume 2019:11 Pages 321—328

DOI https://doi.org/10.2147/BCTT.S184710

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Professor Pranela Rameshwar


Lida A Mina,1 Shannon Lim,2 Shakeela W Bahadur,1 Abdul T Firoz3

1Hematology Oncology Department, Banner MD Anderson Cancer Center, Gilbert, AZ, USA; 2Pharmacy Department, Banner MD Anderson Cancer Center, Gilbert, AZ, USA; 3Science Department, Arizona State University, Tempe, AZ, USA

Correspondence: Lida A Mina
Banner MD Anderson Cancer Center, Suite 400, 2946 E Banner Gateway Dr, Gilbert, AZ 85234, USA
Tel +1 480 256 3676
Fax +1 480 256 4624
Email Lida.mina@bannerhealth.com

Abstract: Breast cancer is the most common type of cancer affecting women in the United States. Triple-negative breast cancer remains the most aggressive molecular subtype secondary to a lack of therapeutic targets. The search for a target has led us to investigate immunotherapeutic agents. Immunotherapy has recently demonstrated significant breakthroughs in various types of cancers that are refractory to traditional therapies including melanoma and Non-Small Cell Lung Cancer (NSCLC). Breast cancer however remains one of the tumors that was initially least investigated because of being considered to have a low immunogenic potential and a low mutational load. Over the past few years, antiPD1/PDL1 drugs have started to make progress in the triple-negative subtype with more promising outcomes. In this report, we review the treatment of triple-negative breast cancer and specifically shed light on advances in immunotherapy and newly approved drugs in this challenging disease.

Keywords: breast cancer, immunotherapy, PD1, PDL1, atezolizumab


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]